Stock Events

Stock Events

Diamyd Medical AB

€0.12

0

-€0.02-17.61% Tuesday 06:02

Statistics

Day High

0.12

Day Low

0.12

52W High

1.69

52W Low

0.09

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DMN.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Novo Nordisk is a leading global healthcare company that focuses on diabetes care, directly competing with Diamyd Medical's diabetes treatment and vaccine development.

Sanofi is involved in the research, development, and marketing of therapeutic solutions including diabetes management, making it a competitor in the diabetes care market.

Eli Lilly is a major player in the pharmaceutical industry with a strong focus on diabetes care and insulin production, competing in the same space as Diamyd Medical.

Merck & Co., Inc. offers a range of diabetes treatments and management solutions, positioning it as a competitor in the diabetes healthcare sector.

AstraZeneca operates in various therapeutic areas, including diabetes, where it competes with Diamyd Medical through its portfolio of diabetes medications.

Bristol-Myers Squibb

Bristol-Myers Squibb has a presence in the diabetes care market through its development of diabetes treatments, making it a competitor.

Tandem Diabetes Care

Tandem Diabetes Care, Inc. specializes in insulin delivery systems, competing in the diabetes management space with innovative technology solutions.

Insulet Corporation is known for its Omnipod Insulin Management System, competing in the diabetes care market with a focus on insulin delivery technologies.

DexCom, Inc. provides continuous glucose monitoring systems for diabetes management, directly competing in the diabetes care technology market.

MediciNova, Inc. is involved in the development of therapeutic products for diseases with unmet medical needs, including diabetes, positioning it as a competitor in the broader diabetes treatment market.

About

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is headquartered in Stockholm, Sweden.

Show more...

CEO

Mr. Niklas Axelsson

Employees

41

Country

Sweden

ISIN

SE0005162880

Listings

0 Comments

Share your thoughts

FAQ

What is Diamyd Medical AB stock price today?▼

The current price of DMN.MU is €0.12 EUR — it has decreased by -17.61% in the past 24 hours. Watch Diamyd Medical AB stock price performance more closely on the chart.

What is Diamyd Medical AB stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Diamyd Medical AB stocks are traded under the ticker DMN.MU.

Is Diamyd Medical AB stock price growing?▼

DMN.MU stock has fallen by -36.69% compared to the previous week, the month change is a -90.27% fall, over the last year Diamyd Medical AB has showed a -83.47% decrease.

How many employees does Diamyd Medical AB have?▼

As of April 29, 2026, the company has 41 employees.

In which sector is Diamyd Medical AB located?▼

Diamyd Medical AB operates in the Health & Wellness sector.

When did Diamyd Medical AB complete a stock split?▼

Diamyd Medical AB has not had any recent stock splits.

Where is Diamyd Medical AB headquartered?▼

Diamyd Medical AB is headquartered in Stockholm, Sweden.